Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchLactoferrinLactoferrin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Lactoferrin for COVID-19: real-time meta analysis of 8 studies

@CovidAnalysis, March 2024, Version 15V15
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rosa 76% 0.24 [0.01-5.85] hosp. 0/82 1/39 Improvement, RR [CI] Treatment Control Rosa -40% 1.40 [0.54-3.64] recov. time 82 (n) 39 (n) Rosa 39% 0.61 [0.40-0.92] viral time 82 (n) 39 (n) Campione 47% 0.53 [0.38-0.72] viral time 32 (n) 32 (n) Campione 56% 0.44 [0.29-0.66] viral time 32 (n) 28 (n) Mann (DB RCT) -203% 3.03 [0.13-73.2] death 1/77 0/79 CT​1 Mann (DB RCT) -203% 3.03 [0.13-73.2] severe case 1/77 0/79 CT​1 Mann (DB RCT) 49% 0.51 [0.05-5.54] hosp. 1/77 2/79 CT​1 Mann (DB RCT) 49% 0.51 [0.10-2.72] hosp. 2/77 4/79 CT​1 Mann (DB RCT) 26% 0.74 [0.45-1.22] no recov. 77 (n) 79 (n) CT​1 Mann (DB RCT) 60% 0.40 [0.16-0.99] no recov. 77 (n) 79 (n) CT​1 Mann (DB RCT) 2% 0.98 [0.68-1.41] no recov. 77 (n) 79 (n) CT​1 Mann (DB RCT) 18% 0.82 [0.51-1.30] no recov. 77 (n) 79 (n) CT​1 Mann (DB RCT) 4% 0.96 [0.74-1.24] no recov. 77 (n) 79 (n) CT​1 Mann (DB RCT) -11% 1.11 [0.90-1.37] viral+ 49/60 36/49 CT​1 Mann (DB RCT) 8% 0.92 [0.50-1.71] PASC 15/67 16/66 CT​1 Algahtani (RCT) 25% 0.75 [0.14-4.09] no recov. 3/36 2/18 Algahtani (RCT) 33% 0.67 [0.17-2.67] no recov. 4/36 3/18 Algahtani (RCT) 0% 1.00 [0.35-2.88] no recov. 8/36 4/18 Algahtani (RCT) 0% 1.00 [0.20-4.95] no recov. 4/36 2/18 Algahtani (RCT) 25% 0.75 [0.24-2.33] no recov. 6/36 4/18 Shousha 79% 0.21 [0.03-1.48] death 1/46 52/501 LAC Matino (DB RCT) -12% 1.12 [0.59-2.10] death 18/113 15/105 LAC Matino (DB RCT) -24% 1.24 [0.62-2.49] death 16/113 12/105 LAC Matino (DB RCT) -45% 1.45 [0.65-3.20] ventilation 14/113 9/105 LAC Matino (DB RCT) -6% 1.06 [0.63-1.79] death/ICU 24/113 21/105 LAC Matino (DB RCT) -34% 1.34 [0.93-1.92] NEWS2/dis. 46/113 32/105 LF-COVID Navarro (DB RCT) -59% 1.59 [0.64-3.93] symp. case 11/104 7/105 LF-COVID Navarro (DB RCT) -23% 1.23 [0.53-2.85] cases 11/104 9/105 Pasinato (RCT) 50% 0.50 [0.05-5.17] cases 1/25 2/25 Lactoferrin COVID-19 outcomes c19early.org March 2024 1 CT: study uses combined treatment Favors lactoferrin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit